Crystal's Coder Hub🔬 CPT 92230 — Fluorescein Angioscopy With Interpretation and Report
“Fluorescein angioscopy with interpretation and report”
Quick Reference
wRVU: 0.46 | Global Period: 000 | Assistant Payable: No | Bilateral Indicator: 3
Rule: Bilateral indicator 3 means this procedure is paid at 200% of the fee schedule when performed bilaterally — it is priced as a unilateral service, and bilateral performance is reportable with modifier -50 (or as two separate line items with -RT and -LT). This is a critical distinction from 92201, 92202, and 92235, which carry bilateral indicator 2. The global period is 000; there is no pre-op or post-op period. CPT 92230 is specifically for angioscopy — real-time observation of retinal vascular fluorescein transit without photographic capture — and is bundled under NCCI with 92235 (fluorescein angiography with multi-frame photography); do not report both on the same date of service.12
📋 Clinical Description
CPT 92230 describes fluorescein angioscopy — a real-time, direct ophthalmoscopic observation of the retinal and choroidal vasculature using intravenously administered sodium fluorescein dye, performed without photographic documentation, with a written physician interpretation and report.1 When fluorescein is injected intravenously, it circulates to the retinal and choroidal vasculature within seconds and fluoresces brilliantly under cobalt blue illumination (excitation ~490 nm, emission ~525 nm), allowing the physician to dynamically observe vascular filling, leakage, staining, and blockage patterns in real time through the ophthalmoscope or biomicroscope.2 The critical distinction between 92230 and 92235 (fluorescein angiography) is the absence of multi-frame photographic capture — angioscopy is purely observational and relies entirely on the physician’s real-time clinical interpretation, whereas angiography captures a permanent photographic record of the fluorescein transit phases.3
Because fluorescein angioscopy produces no permanent photographic record, it is particularly suited for acute clinical settings where vascular dynamics need rapid real-time assessment — such as verifying reperfusion after treatment of an acute retinal artery occlusion, evaluating the extent of retinal vascular leakage in a diabetic patient mid-treatment, or assessing choroidal vascular filling patterns in an inflammatory chorioretinopathy — and the clinical information needed can be captured in the physician’s written interpretation and report without the formal photography workflow.4 However, it is less commonly used in modern retinal practice than 92235 because photographic angiography provides a permanent archivable record that is superior for documentation, comparison across visits, and medicolegal defense. Many payers actively scrutinize 92230 claims given that the procedure leaves no photographic evidence in the medical record.2
This procedure may be performed in the following clinical contexts:
- Acute retinal artery occlusion — treatment monitoring — After intra-arterial or hyperbaric oxygen therapy for a central retinal artery occlusion, angioscopy allows real-time assessment of reperfusion dynamics and whether the arterial block has resolved, without waiting for full angiography setup.3
- Intraoperative or peri-procedural retinal vascular assessment — In settings where rapid vascular evaluation is needed mid-procedure without a full angiography setup, angioscopy can confirm vascular patency, identify areas of non-perfusion, or verify completeness of laser treatment to leaking vessels.
- Diabetic retinopathy — focal leakage survey — Real-time angioscopic observation helps localize areas of active vascular leakage in diabetic macular edema, guiding focal laser photocoagulation targeting, particularly when photography is not immediately available.1
- Inflammatory chorioretinopathy evaluation — In active uveitis or presumed ocular histoplasmosis syndrome, angioscopy assesses choroidal vascular involvement and lesion activity in real time to support treatment urgency decisions.4
- Retinal vein occlusion — ischemia assessment — Angioscopic observation of arteriovenous transit time and capillary perfusion patterns helps characterize the degree of retinal ischemia in branch or central retinal vein occlusion, informing anti-VEGF treatment decisions.2
🔬 Anatomical & Procedural Considerations
| Variant | Mechanism | Key Notes |
|---|---|---|
| BIO-Assisted Fluorescein Angioscopy | Following IV sodium fluorescein injection (typically 500 mg in 5 mL of sterile water), the physician uses a binocular indirect ophthalmoscope equipped with a cobalt blue filter to observe the fluorescent retinal vasculature in real time. The wide field of BIO (60°+ with a 20D lens) allows observation of both the posterior pole and peripheral vasculature during fluorescein transit. | This technique is less commonly used today given the superior resolution and documentation capability of digital angiography cameras. However, it remains valid for 92230 when a fundus camera is not available or when the clinical question requires wide-field peripheral vascular assessment. The physician must document what was observed, the transit characteristics, and the interpretation in a written report — without photographs, the written report carries the entire evidentiary weight.13 |
| Slit Lamp Biomicroscopy with Contact Lens and Cobalt Blue Filter | The slit lamp cobalt blue filter excites the circulating fluorescein; a contact lens (e.g., Goldmann 3-mirror or Volk lens) applied to the anesthetized cornea allows high-magnification real-time observation of posterior pole vascular dynamics and leakage patterns. | This technique offers superior resolution and stereopsis for posterior pole angioscopy compared to BIO, making it useful for macular vascular leakage assessment. The lack of a photographic output is both its defining characteristic (distinguishing 92230 from 92235) and its primary audit vulnerability — document meticulously.24 |
| IV Fluorescein Administration Protocol | Standard IV fluorescein injection is typically 500 mg sodium fluorescein in 5 mL saline, injected rapidly through a peripheral IV. The physician observes the arterial phase (8–12 seconds post-injection), arteriovenous phase (~15–20 seconds), venous phase (~20–30 seconds), and any late staining/leakage. Adverse reactions range from mild nausea to, rarely, anaphylaxis; emergency equipment should be available. | The IV injection of sodium fluorescein and real-time monitoring of the patient for adverse reactions are integral to the procedure and not separately billable. The physician performing the angioscopy must ensure appropriate patient screening for fluorescein allergy and renal function. Because 92230 requires IV dye administration, it is typically not appropriate for office-only settings without IV access and emergency preparedness capability.3 |
Clinical Pearl
Because fluorescein angioscopy (92230) produces no permanent photographic record, the physician’s written interpretation and report is the only clinical documentation of the procedure. In any audit scenario, the examiner will look for a detailed, time-stamped written report documenting what was observed during each vascular phase (arterial, arteriovenous, venous, late) and what clinical conclusions were drawn.2 An audit finding of “FA performed — normal” with no phased description and no photographs is nearly indefensible. If your clinical workflow routinely includes photographic capture, bill 92235 instead — it provides a permanent photographic record, is separately payable, and is far more defensible at audit. Reserve 92230 for situations where photography is truly not performed or not feasible.4
✅ Procedure Includes
- Intravenous sodium fluorescein injection — Administration of the fluorescent dye is integral to the procedure and is not separately billable as a drug supply or injection service.1
- Real-time ophthalmoscopic or biomicroscopic observation of retinal vascular dynamics — The physician’s direct visualization of fluorescein transit through all vascular phases (arterial, arteriovenous, venous, and late) during the examination session is the core clinical service of 92230.2
- Patient monitoring during and after fluorescein injection — Monitoring for adverse reactions including nausea, vomiting, and anaphylaxis is an expected component of the service and is not separately reportable.
- Physician interpretation and written report — The formal written summary documenting observed vascular filling, leakage, staining, blockage, or transit time characteristics, along with clinical conclusions, is a required, bundled element of the 92230 service.3
- Cobalt blue filter application — The illumination modification required to excite fluorescein and visualize vascular dynamics is inherent to the procedure.
- IV access establishment — Placement of a peripheral IV line for fluorescein injection, when performed by office staff or the physician as part of the procedure setup, is considered integral and not separately billable.4
❌ Excludes / Do Not Report Together
| Code | Description | Relationship |
|---|---|---|
| 92235 | Fluorescein angiography (includes multi-frame imaging) with interpretation and report, unilateral or bilateral | 92230 and 92235 are mutually exclusive under NCCI — both involve IV fluorescein dye and retinal vascular assessment, but 92235 includes multi-frame photographic documentation. They cannot be reported together on the same date of service. If photographic angiography is performed, bill 92235 only — it supersedes 92230 and provides a superior evidentiary record.23 |
| 92240 | Indocyanine-green angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral | ICG angiography is a separately billable service from fluorescein angioscopy. However, verify payer-specific bundling policies for same-day billing of 92230 and 92240 — some payers may bundle these services. 92242 (combined FA + ICG on the same day) is not applicable if 92230 is being billed instead of 92235, since 92242 requires full photographic angiography of both dyes. |
| 92004 | Ophthalmological services, new patient, comprehensive | Fluorescein angioscopy performed as an integral part of a routine eye exam evaluation is bundled. For same-day billing of 92230 and a comprehensive eye exam, append modifier -25 to the exam code with documentation of a significant, separately identifiable service.1 |
| 92250 | Fundus photography with interpretation and report | Fundus photography may be separately reportable alongside 92230 when independently medically necessary and documented with its own interpretation and report. However, verify payer-specific policies — some payers may bundle these services when billed on the same date.4 |
Bundling Alert
The most clinically important bundling rule for 92230 is its mutual exclusion with 92235 — you cannot bill angioscopy and angiography together under any circumstance, and no modifier overrides this NCCI bundle.2 In modern retinal practices with fundus cameras, 92235 is almost always the correct code because photographic capture is routinely performed; 92230 should only be billed when photography is genuinely not performed. Upcoding by billing 92230 in addition to 92235 (or vice versa) is a high-visibility audit risk. Additionally, because 92230 carries bilateral indicator 3 (unlike the bilateral indicator 2 codes 92201, 92202, and 92235), bilateral billing rules differ — see the Bilateral Billing Rules section.13
🌳 Code Tree — Medicine: Ophthalmology — Posterior Segment Ophthalmic Procedures
CPT 92002–92499 Medicine: Ophthalmology
│
├── 92201–92202 Ophthalmoscopy Procedures
│ ├── 92201 Ophthalmoscopy, extended; with retinal drawing and scleral depression, peripheral (Global: 000)
│ └── 92202 Ophthalmoscopy, extended; with drawing of optic nerve or macula (Global: 000)
│
├── 92227–92229 Remote Retinal Imaging
│ ├── 92227 Remote imaging for detection of retinal disease (Global: 000)
│ ├── 92228 Remote imaging for monitoring of active retinal disease (Global: 000)
│ └── 92229 Point-of-care autonomous retinal imaging (Global: 000)
│
├── 92230–92260 Posterior Segment Ophthalmic Procedures
│ ├── ▶▶ 92230 ◀◀ Fluorescein angioscopy with interpretation and report ← YOU ARE HERE (Global: 000)
│ ├── 92235 Fluorescein angiography (includes multi-frame imaging) with interpretation and report, unilateral or bilateral (Global: 000)
│ ├── 92240 Indocyanine-green angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral (Global: 000)
│ ├── 92242 Fluorescein angiography and indocyanine-green angiography performed at same encounter with interpretation and report, unilateral or bilateral (Global: 000)
│ └── 92250 Fundus photography with interpretation and report (Global: 000)
│
└── 92260–92499 Additional Ophthalmology Procedures
├── 92260 Ophthalmodynamometry
└── 92283 Color vision examination, extended (eg, anomaloscope or equivalent)
💰 RVU & Reimbursement Profile
| Component | Value |
|---|---|
| Work RVU | 0.46 |
| Global Period | 000 |
| Bilateral Indicator | 3 — Paid at 100% per eye; bilateral = 200% of fee schedule (modifier -50 or -RT/-LT on two lines) |
| Assistant Surgeon | Not applicable |
| Co‑Surgeon | Not applicable |
| Team Surgery | Not applicable |
| PC/TC Split | 0 — No professional/technical component split |
| Modifier -51 Exempt | No |
| Anesthesia | Not applicable |
Bilateral Billing Rules
CPT 92230 carries bilateral indicator 3, which means Medicare pays 100% of the fee schedule for a unilateral procedure and 200% (two times the fee schedule amount) when the procedure is performed bilaterally — unlike bilateral indicator 2 codes (such as 92201, 92202, 92235) where the fee is the same regardless of laterality. When 92230 is performed bilaterally, report it with modifier -50 on a single line at 200% charge, or as two separate line items with modifier -RT on one line and -LT on the other, depending on payer preference. Always verify individual payer billing instructions for bilateral indicator 3 codes — some payers prefer the two-line format over the -50 format.12
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -RT | Right Side | Apply to 92230 when angioscopy is performed unilaterally in the right eye only. Also used as one of two line items when billing bilateral angioscopy with separate RT/LT lines instead of modifier -50. Bilateral indicator 3 makes laterality modifiers appropriate for this code — unlike 92201/92202.1 |
| -LT | Left Side | Apply when angioscopy is performed unilaterally in the left eye only, or as the second line in bilateral RT/LT billing format. |
| -50 | Bilateral Procedure | Apply when fluorescein angioscopy is performed in both eyes during the same session. Bilateral indicator 3 means the bilateral payment is 200% of the unilateral fee schedule rate. Submit as a single line with modifier -50, or per payer preference, as two separate lines with -RT and -LT.2 |
| -25 | Significant, Separately Identifiable E/M Service | Append -25 to the eye exam or E/M code (not to 92230) when a comprehensive or intermediate eye exam is also billed on the same day and represents a significant, separately identifiable service beyond the decision to perform fluorescein angioscopy.3 |
| -59 | Distinct Procedural Service | Apply to 92230 when a payer-specific bundling edit would otherwise package it into another same-day diagnostic service and the services are genuinely distinct with separate documented indications. Do not use -59 to override the NCCI mutual exclusion bundle with 92235.2 |
| -52 | Reduced Services | Use if the angioscopy was initiated but only partially completed due to patient adverse reaction to fluorescein (e.g., severe nausea requiring early termination), with documentation of the reason for incomplete service. |
| -53 | Discontinued Procedure | Apply if the fluorescein injection was prepared but the procedure was terminated before dye was administered due to a patient emergency or clinical contraindication identified at the last moment. |
| -GQ | Via Asynchronous Telecommunications | Applicable if the procedure is conducted and the interpretation is transmitted via store-and-forward telehealth per applicable payer and state rules. |
| -GT | Via Interactive Audio and Video | Applied when telehealth delivery modality is used; confirm 92230 remains on applicable telehealth-eligible procedure lists. |
🩺 Common ICD‑10‑CM Pairings
Primary Diagnosis Group
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| H34.8110 | Central retinal vein occlusion, right eye, with macular edema | No | One of the highest-yield pairings for 92230; real-time angioscopic assessment of arteriovenous transit time and capillary non-perfusion extent helps characterize ischemic vs. non-ischemic CRVO and guides anti-VEGF treatment decisions. Left eye is H34.8120.1 |
| H34.10 | Central retinal artery occlusion, unspecified eye | No | Angioscopy is particularly useful in the acute CRAO setting to evaluate reperfusion dynamics after treatment; code to laterality when documented (H34.11 right, H34.12 left). |
| H35.00 | Nonspecific background retinopathy and retinal vascular changes | No | Broad pairing for early diabetic or hypertensive vascular changes; code to a more specific retinopathy code when documentation supports it (e.g., H36 for retinal disorders in diseases classified elsewhere).2 |
| H30.001 | Unspecified focal chorioretinal inflammation, right eye | No | Inflammatory chorioretinopathies with active vascular involvement may prompt angioscopy for real-time leakage and choroidal vascular assessment.3 |
| H35.3111 | Nonexudative age-related macular degeneration, right eye, early dry | No | Less common pairing — angioscopy is more frequently used for wet AMD and vascular occlusions, but may be performed in dry AMD to evaluate for early conversion to neovascular disease when photography is not immediately available.4 |
Secondary Group
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| H35.3211 | Exudative age-related macular degeneration, right eye, with active choroidal neovascularization | No | When a patient with known wet AMD presents urgently and angioscopy is used for rapid real-time leakage assessment prior to an unplanned anti-VEGF injection, this is the supporting diagnosis. If photography is also performed, bill 92235 instead.2 |
| H35.341 | Macular cyst, hole, or pseudohole, right eye | No | Fluorescein angioscopy may help differentiate full-thickness macular hole from pseudohole by evaluating the foveal vascular zone and RPE leakage pattern in a real-time assessment.3 |
Etiology / Complication
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| E11.3511 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye | Yes — HCC | When fluorescein angioscopy is performed for a diabetic patient with proliferative retinopathy and macular edema, this specific code carries HCC weight and should be coded precisely to the eye and type of retinopathy. Do not default to an unspecified diabetes-with-retinopathy code.14 |
| H35.321 | Exudative age-related macular degeneration, right eye, with active choroidal neovascularization | No | Etiology/complication context when active CNV leakage is the driving indication for the angioscopic assessment; same code as secondary group — context of use determines primary vs. etiology placement.2 |
Coding Specificity Reminder
Retinal vascular occlusion codes (H34.xx) require laterality and, for branch occlusions (H34.2xx), the specific branch (superior temporal, inferior temporal, etc.) documented by the physician. Diabetic retinopathy codes (E10–E13 with .3x–.35x extensions) require the diabetes type, the retinopathy type, and the presence or absence of macular edema — and they are etiology codes that drive the retinal finding, not standalone retinal codes. Never report a retinal finding code (e.g., H35.00) alone for a diabetic patient when the physician documents diabetic retinopathy — the diabetes combination code absorbs the retinopathy and macular edema into one code per ICD-10-CM combination code conventions. AMD staging codes require laterality, type (dry vs. wet), and stage to be coded to the highest level of specificity documented.34
🏥 MS‑DRG Considerations
CPT 92230 is a diagnostic Medicine/ophthalmology service that does not independently drive MS-DRG assignment in the inpatient setting. Fluorescein angioscopy performed on a hospitalized patient — such as a patient admitted for an acute retinal vascular occlusion or infectious endophthalmitis — would be captured on the physician’s professional claim using CPT 92230 and would not influence the facility DRG assignment. The facility DRG is determined by the principal diagnosis and any surgical/therapeutic procedures coded in ICD-10-PCS. Inpatient retinal vascular encounters fall under MDC 02 (Diseases and Disorders of the Eye), most commonly DRG 124 (Other Disorders of the Eye with MCC), DRG 125 (Other Disorders of the Eye with CC), or DRG 126 (without CC/MCC). For diabetic retinopathy-related admissions, the underlying diabetes code is the principal driver. As an inpatient profee coder, capture CPT 92230 on the professional claim when the ophthalmologist performs real-time fluorescein angioscopy at the bedside or in the procedure suite; the facility claim uses ICD-10-PCS for any therapeutic interventions performed during the same admission.14
🔧 ICD‑10‑PCS Equivalents
Note
CPT 92230 involves IV dye administration and real-time physician observation of retinal vascular dynamics. In ICD-10-PCS, the closest root operation is Inspection (visual exploration) under Section 0 (Medical and Surgical) for the ophthalmoscopic component, or Measurement under Section 4 for the vascular assessment component. The IV fluorescein administration could theoretically be coded as an Introduction (Section 3 — Administration) in addition to the observation, but in practice ICD-10-PCS does not have a dedicated “fluorescein angioscopy” procedure code.
| PCS Code | Full Description | Modality |
|---|---|---|
| 08J0XZZ | Inspection of Right Eye, External Approach | Physician visual inspection of the right eye — captures the ophthalmoscopic observation component of angioscopy |
| 08J1XZZ | Inspection of Left Eye, External Approach | Physician visual inspection of the left eye |
| 3E0C3GC | Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach | Closest PCS code for IV dye introduction — highly approximate; fluorescein is not a therapeutic substance, making this a poor functional equivalent |
| 4A07XVZ | Measurement of Eye, Ophthalmologic, External Approach | Ophthalmologic measurement — applicable when vascular dynamics are being quantitatively assessed alongside real-time visualization |
PCS Character Analysis (using 08J0XZZ as primary example)
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 0 | Medical and Surgical — covers physician-performed procedures on body parts including diagnostic inspection. |
| 2 | Body System | 8 | Eye — encompasses all ocular structures including the retina, choroid, and retinal vasculature. |
| 3 | Root Operation | J | Inspection — visually and/or manually exploring a body part; the most accurate PCS root operation for the ophthalmoscopic retinal vascular observation component of angioscopy.1 |
| 4 | Body Part | 0 | Right Eye — body part value 0 for the right globe; use 1 for the left eye, or X for unspecified/bilateral context. |
| 5 | Approach | X | External — fluorescein angioscopy is performed through the dilated pupil using ophthalmoscopic instrumentation without any incision or penetration of the eye wall. |
| 6 | Device | Z | No Device — no implantable or retained device is used during the diagnostic observation; the indirect ophthalmoscope and contact lens are external instruments. |
| 7 | Qualifier | Z | No Qualifier — no additional specification is defined for this inspection procedure in the current PCS table. |
Root Operation Comparison
- Inspection (J) vs. Introduction (3E0, Section 3 Administration): The fluorescein injection component of 92230 involves administering a substance into the bloodstream (peripheral IV), which technically maps to the Administration section (3E0xxxx) in PCS. However, since the clinical intent of the entire procedure is diagnostic observation of the retinal vasculature — not therapeutic substance introduction — the Inspection root operation (08J0XZZ) most accurately captures the dominant purpose of the service in an inpatient PCS context.
- Section 4 Measurement vs. Section 0 Inspection for vascular dynamics: If the clinical documentation emphasizes quantitative assessment of retinal arteriovenous transit time or vascular patency (a measurable physiological parameter), Section 4 Measurement (4A07XVZ) may be a reasonable PCS alternative. If the documentation emphasizes the physician’s observational survey of retinal anatomy and pathology during dye transit, Section 0 Inspection is more appropriate.
- Practical inpatient PCS applicability: PCS codes for fluorescein angioscopy are rarely reported on facility claims because this is predominantly an outpatient/office-based diagnostic service. When it does occur inpatient, facilities may elect not to code the diagnostic observation separately in PCS, as it does not affect DRG assignment and does not generate separate facility reimbursement beyond the DRG rate.4
📝 Coding Examples
Example 1 — Acute Central Retinal Vein Occlusion Evaluation, Right Eye
Clinical Scenario:
A 68-year-old established patient with hypertension and diabetes presents urgently with sudden-onset painless vision loss in the right eye beginning this morning. On examination, the physician observes widespread flame-shaped hemorrhages in all four quadrants, disc edema, and dilated tortuous retinal veins consistent with central retinal vein occlusion. The fundus camera is unavailable due to a technical malfunction. The physician performs fluorescein angioscopy using a slit lamp with cobalt blue filter and 90D contact lens, administering IV sodium fluorescein and directly observing the arteriovenous transit time (prolonged at approximately 28 seconds), areas of capillary non-perfusion in the temporal periphery, and active leakage at the disc and macula. An intermediate eye exam is also performed and documented. The physician writes a detailed interpretation and report documenting each phase observed and concluding the occlusion is likely ischemic based on the non-perfusion extent.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 92012-25 | Intermediate established patient eye exam; modifier -25 on the exam code to identify a significant, separately identifiable evaluation service. The examination included anterior segment, IOP, and clinical assessment of the CRVO independent of the angioscopy.1 |
| CPT 2 | 92230-RT | Fluorescein angioscopy, right eye only; modifier -RT applied because bilateral indicator 3 permits laterality modifiers and the service is unilateral. Written interpretation and report documents arteriovenous transit time, non-perfusion extent, and clinical conclusions.2 |
| PDx | H34.8110 | Central retinal vein occlusion, right eye, with macular edema — document to full specificity as supported by the physician’s examination findings. |
Note
Because the fundus camera was unavailable, 92235 (fluorescein angiography with multi-frame photography) cannot be billed — there are no photographs. CPT 92230 is the correct code when only real-time observation without photographic capture occurs. Document in the medical record the reason photography was not performed to support the 92230 claim if audited, as payers may question why angioscopy was performed instead of angiography.3
Example 2 — Bilateral Diabetic Retinopathy Vascular Assessment
Clinical Scenario:
A 58-year-old established patient with poorly controlled type 2 diabetes and bilateral non-proliferative diabetic retinopathy presents for a monitoring visit. The retinal specialist performs an intermediate exam and then conducts fluorescein angioscopy of both eyes using BIO with cobalt blue filter to evaluate vascular leakage patterns and capillary non-perfusion distribution bilaterally. The physician observes mild perifoveal capillary loss in the right eye and active microaneurysm leakage temporal to the fovea in the left eye. A comprehensive bilateral written interpretation and report is authored documenting findings in each eye by quadrant with transit phase observations and clinical management recommendations.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 92012-25 | Intermediate established patient eye exam; -25 on the exam code. |
| CPT 2 | 92230-50 | Fluorescein angioscopy, bilateral; modifier -50 applied because bilateral indicator 3 means bilateral performance is reimbursed at 200% of the unilateral fee. Submit per payer billing format preference (-50 on one line at 200% charge, or two lines with -RT and -LT).12 |
| PDx | E11.3412 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye — code the more severe eye as the primary diagnosis; include the right eye manifestation code as well per ICD-10-CM sequencing guidelines. |
Warning
Do NOT add 92235 to this claim — 92230 and 92235 are mutually exclusive under NCCI with indicator 0 and cannot be billed together on the same date under any modifier circumstance. If photographs were also taken today, bill 92235 instead of 92230 — do not bill both. The distinction between these two codes must reflect what was actually performed and documented.23
Example 3 — Choroidal Inflammatory Lesion, Established Patient, No Concurrent Exam
Clinical Scenario:
A 44-year-old established patient with known presumed ocular histoplasmosis syndrome (POHS) returns specifically for an angioscopic evaluation of a juxtafoveal choroidal lesion in the left eye that the physician noted was enlarging at last month’s visit. No comprehensive examination is performed today. The physician administers IV fluorescein and performs slit lamp angioscopy using a contact lens, observing early hyperfluorescence and late leakage at the juxtafoveal lesion consistent with active subretinal neovascularization. A detailed written interpretation and report documents the leakage pattern, lesion borders, and clinical decision to initiate anti-VEGF therapy. No photographs are taken today.
| Field | Code | Rationale |
|---|---|---|
| CPT | 92230-LT | Fluorescein angioscopy, left eye only; modifier -LT applied per bilateral indicator 3 rules since the service is unilateral. No concurrent eye exam billed today. Written interpretation and report documents the angioscopic findings in full detail.14 |
| PDx | H30.091 | Unspecified focal chorioretinal inflammation, right eye — use the left eye equivalent H30.092 for the left eye, or the most specific chorioretinal inflammation code supported by documentation (e.g., H30.091–H30.099 for focal choroiditis/chorioretinitis by laterality). |
Global period reminder
CPT 92230 has a global period of 000 — only the day of service is bundled into the payment, with no pre-op or post-op period. If this patient receives an intravitreal anti-VEGF injection (67028) at a subsequent visit this same week, the 92230 performed today is separately billable from the injection since they occur on different dates of service. If both the angioscopy and the injection are performed on the same calendar day, NCCI bundling between 92230 and 67028 should be verified — if they are separately payable, modifier -59 on 92230 may be needed with documentation that the angioscopy was a distinct diagnostic service performed prior to the independent clinical decision to inject.24
⚠️ Common Coding Pitfalls
- Pitfall 1 — Billing 92230 when photography was actually performed: CPT 92230 is specifically for angioscopy without photographic capture. If the practice’s fundus camera operator captured any fluorescein angiography images during the same IV fluorescein session, the correct code is 92235 — not 92230. Billing 92230 when angiographic photographs exist in the chart misrepresents the service rendered and constitutes miscoding.2
- Pitfall 2 — Billing 92230 and 92235 on the same date: NCCI bundles these two codes with indicator 0 — they are mutually exclusive and cannot be billed together regardless of what modifier is appended. This is a clear overcoding error and a high-visibility audit target.23
- Pitfall 3 — Failing to apply laterality modifiers correctly: Unlike 92201, 92202, and 92235, CPT 92230 carries bilateral indicator 3, meaning laterality modifiers (-RT, -LT) and bilateral modifier (-50) are appropriate and affect payment. Forgetting to apply -RT or -LT on a unilateral claim, or failing to apply -50 for bilateral angioscopy, will result in incorrect payment. This is a frequent billing error in practices that treat all ophthalmology diagnostic codes as bilateral indicator 2 codes.1
- Pitfall 4 — Inadequate written interpretation and report: Because 92230 produces no photographs, the written report is the only evidentiary record of the procedure. A bare-minimum note such as “FA performed — NV noted” is not defensible at audit. The report must document IV fluorescein administration, real-time vascular phase observations (arterial, arteriovenous, venous, late), specific findings by location, and clinical conclusions. Absent this detail, the claim cannot be substantiated.3
- Pitfall 5 — Performing 92230 in settings without emergency preparedness: IV sodium fluorescein carries a small but real risk of severe anaphylaxis. Performing fluorescein angioscopy in office settings without appropriate IV access capability, emergency medications (epinephrine, antihistamines), and resuscitation equipment creates both a patient safety risk and a liability exposure. Ensure your practice setting meets the clinical standards for IV dye administration before billing this code.4
- Pitfall 6 — Confusing 92230 with 92235 for routine retinal practice: In the vast majority of contemporary retinal practices with digital fundus cameras, 92235 (fluorescein angiography with multi-frame imaging) is the appropriate and more defensible code because it produces a permanent photographic record. CPT 92230 should be a relatively infrequent code used only in specific circumstances where photography is genuinely not performed. High-volume billing of 92230 in a practice with functioning fundus cameras is a red flag that may trigger payer audits.23